The clinical findings and outcomes of symptomatic pregnant women diagnosed with or suspected of having coronavirus disease 2019 in a tertiary pandemic hospital in Istanbul, Turkey

Ismail Alay[1], Sukru Yildiz[1], Cihan Kaya[1], Kadriye Kart Yasar[2], Ozlem Altuntas Aydin[2], Hayat Kumbasar Karaosmanoglu[2], Banu Aydeniz[3], Ozgul Salihoglu[4], Levent Yaşar[1] and Murat Ekin[1]

[1]*Department of Obstetrics and Gynecology, University of Health Sciences Turkey, Bakirkoy Dr. Sadi Konuk Education and Training Hospital, Istanbul, Turkey*

[2]*Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Turkey, Bakirkoy Dr.Sadi Konuk Education and Training Hospital, Istanbul, Turkey*

[3]*Departent of Physical Medicine and Rehabilitation, University of Health Sciences Turkey, Bakirkoy Dr. Sadi Konuk Education and Training Hospital, Istanbul, Turkey*

[4]*Department of Pediatrics, Division of Neonatology, University of Health Sciences Turkey, Bakirkoy Dr. Sadi Konuk Education and Training Hospital, Istanbul, Turkey*

Abstract

Aim: To observe the clinical course of symptomatic pregnant women diagnosed with or suspected of having COVID-19.

Methods: This study analyzed the clinical and laboratory results of 27 patients with real-time polymerase chain reaction (RT-PCR)-confirmed COVID-19 and 25 patients with a suspected COVID-19 diagnosis based on their symptoms and chest computed tomography (CT) findings. The patients' coagulation parameters and acute-phase reactants were evaluated both before and after treatment. The maternal and neonatal outcomes were also reviewed.

Results: The mean duration of hospitalization was 6.1 ± 3 days. The gestational age of the patients ranged from 6w2d to 40w2d. Thirty-five patients' CT scan findings suggested viral pneumonia. Four patients delivered vaginally, and 10 patients underwent a cesarean section during the study period. Four of the cesarean deliveries were indicated due to COVID-19 hypoxemia-related fetal distress. Four patients were admitted to the intensive care unit (ICU) after the cesarean section.

Conclusion: Early hospitalization and medical treatment can alleviate symptoms, improve the clinical course and reduce the need for ICU in symptomatic pregnant patients with suspected or confirmed COVID-19. Chest CT scans are a suitable option for suspected but unconfirmed COVID-19 infection.

Key words: chest CT scan, COVID-19, novel coronavirus-2019, pregnancy, SARS-Cov-2.

Introduction

The new coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome 2 (SARS-CoV-2) virus, is an enveloped RNA virus in the *betacoronaviridae* family that was first detected in Wuhan City, China, in December 2019.[1] The virus quickly spread to other countries and became a major health problem that caused severe viral pneumonia and death. The World Health Organization declared COVID-19 a pandemic on 11 March 2020.[2] The spread of the virus is thought to occur mainly via respiratory droplets. Although most people infected with the SARS-CoV-2 virus are asymptomatic or have mild symptoms, approximately 5% experience severe viral pneumonia, which requires mechanical ventilation support.[3,4]

Currently, the gold standard method to diagnose COVID-19 is the real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay, which has some limitations, including difficulty in testing higher numbers of suspected patients, the necessity of maintaining cold chain rules, the occurrence of errors during the sampling process, and a longer duration required for obtaining the test results. In contrast, thorax computed tomography (CT) scanning enables a prompt diagnosis because the appearance of bilateral, peripheral multi-lobar ground-glass opacities or consolidation has a high sensitivity for COVID-19 infection.[5,6]

Pregnant women are at high risk for COVID-19 and its related complications due to the immune, cardiac and pulmonary changes that take place during pregnancy. Both the data from previous coronavirus infections (Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Coronavirus) and the current lack of data regarding this new coronavirus infection have increased concerns regarding the effects of COVID-19 on pregnant women and their newborns.[7,8]

There is still a lack of clinical and epidemiological data in the literature regarding pregnancy and COVID-19. Studies of pregnant women with COVID-19 have been small and generally have included only third-trimester pregnancies; consequently, little is known about the clinical progression of the disease in the first and second trimesters and about the effect of the disease on coagulation parameters.[9–15] Based on the current literature, the SARS-CoV-2 virus has not been vertically transmitted, and pregnant women with COVID-19 have similar clinical features to non-pregnant patients.

This study aimed to observe the clinical features, laboratory findings, and perinatal and neonatal outcomes of symptomatic hospitalized pregnant women diagnosed with or suspected of having COVID-19 in a tertiary pandemic hospital.

Methods

This retrospective study was conducted at the Obstetrics and Gynecology Department of a tertiary healthcare center in Turkey designated for COVID-19 patients within the scope of national precautions for the COVID-19 outbreak. Ethics approval was obtained from the hospital's local ethics committee (Approval number 2020/158). The clinical outcomes, sociodemographic characteristics and radiological and laboratory features of 52 pregnant women hospitalized between 25 March and 25 May 2020 due to suspected or diagnosed COVID-19 infection were reviewed; 27 of these women tested positive for COVID-19 infection following a RT-PCR test. The remaining 25 patients were given a suspected COVID-19 diagnosis according to their symptoms and CT scan findings. We excluded patients who were asymptomatic, had negative RT-PCR results and refused hospitalization.

The sociodemographic characteristics and medical histories of the patients were obtained upon admission. Gestational age was calculated according to the date of the patients' last menstrual period. After routine physical and obstetric examinations that included obstetric ultrasonography, the patients were transferred to the COVID-19 quarantine service and hospitalized in isolated patient rooms. CT scans were performed after covering the entire abdomen with a lead blanket to protect the fetus from the radiation. Thoracic CT scan findings were reviewed from radiologists' reports accessed from the computer-based database. Written informed consent for radiologic imaging and medical therapy was obtained from all patients. Nasal and pharyngeal swabs for the RT-PCR tests were performed, and the samples were transferred to national virology laboratories for results following cold chain rules.

Coagulation parameters (including activated partial thromboplastin time, prothrombin time, fibrinogen, international normalized ratio, and D-dimer), platelet, red blood cell, lymphocyte and neutrophil counts, kidney and liver function tests, and hemoglobin, hematocrit, C-reactive protein (CRP), ferritin and

procalcitonin levels, were evaluated at admission and again at 2-day intervals during the hospital stay. Both admission and discharge values for D-dimer, fibrinogen, ferritin, procalcitonin and CRP are presented. The participants were categorized according to their gestational age as first-, second- or third-trimester pregnancies.

All patients received oxygen support, enoxaparin, and hydroxychloroquine treatment. Other antiviral and antibiotic medications (i.e., oseltamivir, azithromycin, lopinavir/ritonavir, favipiravir, and ceftriaxone) were administered based upon the clinical conditions of the patients. The applied medical treatment protocols were as follows: hydroxychloroquine, 400 mg p.o. every 12 h on the first day and 200 mg p.o. every 12 h on the following days; oseltamivir, 75 mg p.o. twice a day; favipiravir, 1600 mg p.o. every 12 h on the first day and 600 mg p.o. twice a day on the following days; lopinavir 200 mg / Ritonavir 50 mg two capsules p.o. twice a day; azithromycin 500 mg p.o. on the first day and 250 mg p.o. on the following days; ceftriaxone 1 gr i.v. every 12 h. The duration of medical treatment was determined by infectious disease specialists based on the clinical conditions of the patients and laboratory results.

Labor and delivery were conducted according to the national safety guidelines with all healthcare workers wearing personal protective equipment. The neonatal outcomes of the patients delivered during follow-up were evaluated, including neonatal ICU admission, fetal weight, cord blood pH, first- and fifth-minute Apgar score, and the RT-PCR results of neonatal oropharyngeal and nasal swab samples. Newborn babies were isolated from their mothers in the neonatal care unit and were given collected breastmilk.

Statistical analysis

The data analysis was performed with SPSS software (IBM SPSS Statistics for Windows, Version 20.0 IBM Corp.). The categorical variables are presented as the numbers and frequencies. Continuous variables are shown as the mean, the standard deviation and the minimum and maximum values. The paired-sample t-test and Wilcoxon Signed Rank test were used to compare the D-dimer, fibrinogen, ferritin, procalcitonin and CRP levels both before and after treatment. χ^2 and Fisher's exact tests were used to evaluate the association between RT-PCR test results and clinical symptoms. A P-value of <0.05 was considered statistically significant.

Results

The mean age of the patients was 30 ± 5.7 years. The demographic characteristics and laboratory results of the patients are presented in Tables 1 and 2. The mean duration of hospitalization was 6.1 ± 3 days. Five, 24, and 23 of the cases were in the first, second and third trimesters of pregnancy, respectively. The median gestational age of the patients was 26 weeks (range: 6w2d–40w2d).

Table 1 Sociodemographic, clinical characteristics and laboratory results of the study population

	Minimum	Maximum	Mean	SD
Age (years)	18	42	30.0	5.7
BMI (kg/m^2)	19.6	46.8	28.3	4.8
Hospitalization (days)	2	20	6.1	3.0
Gravidity	1	10	3.1	2.1
Parity	0	8	2.9	2.0
Gestational Age (weeks/days)	6w2d	40w2d	26w1d	8w6d
RBC (x10^6/mm^3)	2.6	5.1	3.9	0.4
WBC (cells/mm^3)	3390	26 810	8902.8	4149.1
Lymphocyte (cells/mm^3)	240	3270	1442.5	614.8
Neutrophil (cells/mm^3)	1030	22 640	6511.1	3805.8
Platelet (cells/mm^3)	117 000	406 000	216 576.9	64 858.6
Hemoglobin (gr/dL)	6.5	14.9	11	1.5
Hematocrit (%)	21	44.2	33.0	4.2
aPTT (sn)	21.4	49.5	35.7	4.3
PT (sn)	10.9	15.9	13.1	1.3
INR	0.8	1.2	0.9	1.1

aPTT, activated partial thromboplastin time; BMI, body mass index; d, days; INR, international normalized ratio; PT, prothrombin time; RBC, red blood cell; SD, standard deviation; w, weeks; WBC, white blood cell.

Table 2 Frequencies of the sociodemographic characteristics and clinical features of the study population

	n	%
Smoking		
Yes	1	1.9
No	47	90.4
Ex-smoker	4	7.7
Chronic disease		
Diabetes mellitus	1	1.9
Hipotroidi	2	3.8
Ankylosing spondylitis	1	1.9
Asthma	2	3.8
Ascending aortic aneurysm	1	1.9
Complaints at admission		
Fever	9	17.3
Cough	38	73.0
Headache	5	9.6
Shortness of breath	21	40.3
Sore throat	7	13.4
Fatigue	19	36.5
Loss of smell and taste	3	5.7
Diarrhea	4	7.6
Chest CT findings (n = 40)		
Patch like shadows	22	55
Ground glass opacity	32	80
Fiber shadows	6	15
Pleural efusion	6	15
Atelectasis	7	17.5
Crazy paving sign	1	2.5
Halo sign	1	2.5
No pneumonia sign	5	12.5
Gestational age		
First trimester	5	9.6
Second trimester	24	46.2
Third trimester	23	44.2
RT-PCR results		
Positive	27	52
Negative	25	48

CT, computed tomography; RT-PCR, real-time reverse transcriptase-polymerase chain reaction.

Twenty-seven of the patients had RT-PCR-confirmed diagnoses of COVID-19. The remaining 25 symptomatic patients' CT findings suggested viral pneumonia. The distribution of symptoms was as follows: fever, 17.3%; cough, 73%; fatigue, 36.5%; sore throat, 13.4%; shortness of breath, 40.3%; loss of smell and taste, 5.7%; abdominal pain and diarrhea, 7.6%; and headache, 9.6%. There was no significant difference between RT-PCR test positive and negative patients in terms of clinical symptoms including fever ($P = 0.621$), cough ($P = 0.279$), headache ($P = 0.575$), shortness of breath ($P = 0.609$), sore throat ($P = 0.267$), fatigue ($P = 0.071$), loss of smell and taste ($P = 0.507$) and diarrhea ($P = 0.262$).

Pulmonary CT scanning was performed in 40 of the patients. The pulmonary CT scan images showed ground-glass opacity in 80%, patch-like shadows in 55%, fiber shadows in 15%, pleural effusion in 15%, atelectasis in 17.5%, a crazy-paving sign in 2.5% and a halo sign in 2.5%.

The frequencies of patients who were administered oseltamivir, lopinavir/ritonavir, favipiravir, azithromycin and ceftriaxone in addition to hydroxychloroquine treatment were 19.2%, 11.5%, 5.8%, 21.2% and 5.8%, respectively. However, 28 (54.9%) patients were administered hydroxychloroquine treatment alone.

Four patients delivered vaginally, and 10 patients underwent a cesarean section during the study period. Four of the cesarean deliveries were performed due to fetal distress after a sudden decrease in maternal oxygen saturation related to COVID-19 disease. Eight patients had preterm deliveries (four early preterm and four late preterm deliveries) during the study period.

Four of the delivered patients were admitted to the ICU following cesarean section. All of these patients were admitted with cough and shortness of breath. The laboratory results, clinical features and pulmonary CT scan images of these patients are presented in Table 3 and Figure 1. Case 4 had a contact history with a COVID-19 patient. On the third day of hospitalization, a sudden decrease on her oxygen saturation was observed while she was under nasal oxygen support and hydroxychloroquine treatment and an emergency cesarean delivery was performed due to hypoxemia related fetal distress. Case 6 was diagnosed preeclampsia during follow-up due to higher blood pressure levels and 5 g proteinuria in her 24-h urine analysis. She received alpha methyldopa, MgSO4, betamethasone and hydroxychloroquine treatment. On the fifteenth day of hospitalization, she had a cesarean delivery due to the absence of end-diastolic flow and a blood pressure level above 160/100 mmHg. Case 12 underwent cesarean delivery on the third day of hospitalization due to suddenly decreased oxygen saturation up to 70% under nasal oxygen support. Case 14 had a 27-week in vitro fertilization pregnancy and was diagnosed preeclampsia the month before her admission. Her blood pressure was 170/110, and her oxygen saturation was 60% at admission. An emergency cesarean section was performed due to maternal hypoxemia and severe preeclampsia.

Throat swab samples were obtained from all newborn babies within 24 h of birth; none were positive

Table 3 Clinical characteristics and blood test results of patients admitted to the ICU

	Case 4	Case 6	Case 12	Case 14
Blood test results at hospitalization				
WBC (cells/mm^3)	10 800	10 230	9140	20 580
Neutrophil (cells/mm^3)	9410	8030	7350	18 140
Lymphocyte (cells/mm^3)	910	1530	1090	1780
Platelet (cells/mm^3)	223 000	164 000	186 000	335 000
D-Dimer (μg FEU/mL)	0.74	0.69	0.04	1.79
Fibrinogen (mg/dL)	574	467	555	574
INR	0.98	1.00	0.96	1.06
Ferritin (μg/L)	94	25	59	8
Procalcitonin (ng/mL)	0.68	0.04	0.24	0.12
CRP (mg/L)	153	17	113	45
Blood test results at discharge				
WBC (cells/mm^3)	6180	6890	13 810	4390
Neutrophil (cells/mm^3)	3440	4390	10 990	2890
Lymphocyte (cells/mm^3)	1950	1960	1710	940
Platelet (cells/mm^3)	445 000	137 000	397 000	274 000
D-Dimer (μg FEU/mL)	0.87	0.26	0.48	4.56
Fibrinogen (mg/dL)	527	483	401	401
INR	1.12	0.94	1.3	1.07
Ferritin (μg/L)	75	37	24	378
Procalcitonin (ng/mL)	0.03	0.02	0.05	0.05
CRP (mg/L)	15	13	10	9
Hospitalization at ICU (days)	15	2	10	3
Age (years)	32	35	32	33
Gravidity	3	2	3	1
Parity	1	1	1	0
BMI (kg/m^2)	27.5	35.8	30.4	29.7
SaO$_2$ at admission (%)	95	97	94	60
Chronic disease	—	Ascending aortic aneurysm	—	—
Complaint at admission	Cough, shortness of breath	Cough, shortness of breath	Cough, shortness of breath	Cough, shortness of breath
RT-PCR result	Positive	Negative	Positive	Negative
Duration Between hospitalization and ICU admission (days)	3	15	3	0

BMI, body mass index; CRP, C-reactive protein; CT, computed tomography; ICU, intensive care unit; INR, international normalized ratio; RT-PCR, real-time reverse transcriptase-polymerase chain reaction; WBC, white blood cell.

for COVID-19. Table 4 shows the maternal and neonatal data of patients delivered during the study period.

While the CRP and procalcitonin levels significantly decreased after treatment, there were no significant differences before or after treatment in terms of the fibrinogen, ferritin, and D-dimer levels (Table 5).

Discussion

Although some data have been published since the beginning of the COVID-19 pandemic, the literature on pregnant patients is scant. Della Gatta et al.'s[16] systematic review evaluated just 50 patients with an RT-PCR-confirmed diagnosis. The median maternal age was 30 years, and the median gestational age at diagnosis was 36 weeks. Of the 48 patients who were delivered, there were only two vaginal births, and 39% of the patients had a preterm delivery; just two of the patients were in the second trimester. In our study, most pregnant patients were in their thirties, and nearly half were in the second trimester. Twenty-seven patients had an RT-PCR-confirmed diagnosis of COVID-19. However, all remaining patients were symptomatic and had positive CT findings that

Figure 1 Pulmonary CT scan images of the patients who were admitted to the intensive care unit after cesarean section. **Case 4.** Ground-glass opacity, patch like shadows **Case 6.** Ground-glass opacity, patch like shadows, atelectasis, fiber shadows, pleural effusion. **Case 12.** Ground-glass opacity, patch like shadows. **Case 14.** Ground glass opacity, patch like shadows, fiber shadows, pleural effusion, atelectasis.

suggested viral pneumonia. Ten out of 14 patients had cesarean deliveries; eight patients had preterm deliveries and 4 were late preterm deliveries beyond 34 weeks. In only four patients, the cesarean indication was fetal distress from severe COVID-19-related hypoxemia. The other cesarean deliveries were due to non-COVID-19-related indications. Similarly, only two of Della Gatta *et al.*'s[16] patients were admitted to the ICU. These results confirm that the outcomes of COVID-19 pregnancies are generally favorable.

Another different finding was the distribution of symptoms. Our study had fewer fevers than previously reported (17.3% vs. 48%, respectively), while cough was the main complaint of prior patients.[16] This discrepancy may be related to our early treatment protocol with hydroxychloroquine and antiviral therapy. All of the newborn babies in our investigation were negative for COVID-19, which was similar to Della Gatta *et al.*'s results.[16] According to Yang *et al.*,[17] fever was the main complaint in 87% of their 114 pregnant cases, which differed from our results. Adverse outcomes, including stillbirth (1.2%) and neonatal death,

were reported in only 1.2% of these patients.[17] While 21.3% of Della Gatta *et al.*'s participants had preterm deliveries,[16] the preterm delivery rate in our study was 15.3%. We also had four preterm deliveries that were unrelated to COVID-19. Among the four preterm deliveries due to COVID-19-related hypoxemia, two of them were late preterm deliveries and the others were early preterm deliveries.

We used chest CT scanning to confirm the presence of COVID-19 disease because the detection rate of RT-PCR is relatively low and may be related to improper sampling techniques. Chest CT played an important role in the diagnosis and management of our patients; it was used in 40 of our reviewed patients and has a good diagnostic value for COVID-19-related pneumonia. In contrast, the RT-PCR analysis has some limitations, including false-negative results due to inappropriate sample collection or procedural errors. It was also time-consuming to start medication at the beginning of a pandemic. This limitation of RT-PCR led us to the nearly routine use of chest CT for the early diagnosis and hospitalization of pregnant

Table 4 Maternal and neonatal outcomes of the patients delivered during the study period

Case number	Delivery type	Gestational age (weeks/days)	CS Indication	Maternal ICU admission	Birth Weight (g)	1. and 5. Min. APGAR	Neonatal ICU admission	Cord Blood Ph	Neonatal RT-PCR result
1	CS	35w6d	Fetal distress[†]	No	2380	8/9	No	7.38	Negative
2	SVD	40w2d		No	3510	9/10	No	7.35	Negative
3	CS	37w2d	CS history	No	3635	9/10	No	7.37	Negative
4	CS	34w2d	Fetal distress[†]	Yes	2305	7/8	No	7.35	Negative
5	CS	35w6d	Breech presentation	No	2720	8/9	No	7.26	Negative
6	CS	26w5d	Preeclampsia	Yes	665	7/8	Yes	7.32	Negative
7	CS	38w4d	CS history	No	2650	8/9	No	7.25	Negative
8	SVD	40w2d		No	3620	7/9	No	7.20	Negative
9	CS	33w5d	Preeclampsia	No	1500	7/8	Yes	7.24	Negative
10	CS	39w1d	CS history	No	3380	7/8	No	7.12	Negative
11	SVD	40w1d		No	3500	8/9	No	7.32	Negative
12	CS	30w3d	Fetal distress[†]	Yes	1565	6/8	Yes	7.15	Negative
13	SVD	36w4d		No	2400	8/9	No	7.37	Negative
14	CS	27w	Preeclampsia and Fetal distress[†]	Yes	1000	2/6	Yes	7.16	Negative

[†]COVID-19 related maternal hypoxemia. and CS, cesarean delivery; ICU, intensive care unit; RT-PCR, real-time reverse transcriptase-polymerase chain reaction; SVD, spontaneous vaginal delivery.

patients. Ground-glass opacity is the earliest manifestation that has been reported in up to 98% of COVID-19 patients[18] and was present in 80% of our patients. In a different series, multifocal, patchy or segmental consolidations were also identified in 2–64% of patients.[18] Patch-like shadows were the second most-common finding in our COVID-19 patients. The crazy-paving sign, which is attributed to alveolar edema and acute interstitial inflammation, has been reported in 5–36% of COVID-19 patients.[19] We found this sign in only 2.5% of our patients. This discrepancy may be related to the severity of the patients' conditions, as we began medication upon hospitalization; as a result, we had few patients with severe conditions who required ICU hospitalization.

In their retrospective study that included 140 patients diagnosed with COVID-19, Liu et al.[20] investigated the prognostic value of inflammatory markers, including interleukin-6, CRP and procalcitonin, and found that interleukin-6 and CRP can effectively assess the disease severity and predict its outcome. To our knowledge, there are no published data regarding the efficacy of inflammatory markers in pregnant COVID-19 patients. In our study, CRP and procalcitonin levels significantly decreased after medical treatment with hydroxychloroquine.

COVID-19 increases the risk of intravascular thrombosis, and a prophylactic dose of a low-molecular weight heparin (LMWH) is recommended for patients hospitalized due to COVID-19.[21] Because prophylactic LMWH is a routine clinical treatment for all pregnant patients hospitalized for more than 2 days, we were able to begin enoxaparin treatment immediately. Although there is not yet enough evidence to support our suspicion, we believe that LMWH treatment may facilitate the early recovery of pregnant patients with COVID-19.

Vertical transmission of the SARS-CoV-2 virus has not been demonstrated, but little is known about the risk of adverse fetal and neonatal outcomes in patients infected during their first and second trimesters. Our study included 5 first trimester and 24 s-trimester patients who will be closely monitored, and the outcome of these pregnancies may shed light on this issue along with cumulative data from around the world.

One strength of this study was that it included a higher number of first- and second-trimester pregnant patients with COVID-19 than other published studies. In addition, the evaluation of acute-phase reactants and coagulation parameters both before and after treatment also contributed to the literature. The study's

Table 5 Comparison of patients' acute phase reactants and D-Dimer levels before and after treatment

	Before treatment (mean ± SD)	After treatment (mean ± SD)	95% CI (lower–upper)	*P* value
Procalcitonin overall (ng/mL)	0.09 ± 0.13	0.06 ± 0.10	0.000–0.000	<0.001
First trimester	0.03 ± 0.01	0.01 ± 0.00	0.240–0.57	0.102
Second trimester	0.07 ± 0.08	0.03 ± 0.03	0.014–0.019	0.022
Third trimester	0.13 ± 0.17	0.10 ± 0.14	0.014–0.019	0.021
Ferritin overall (μg/L)	47.8 ± 65.3	114.8 ± 231	0.072–0.083	0.078
First trimester	47.4 ± 60.2	51.7 ± 54.6	0.868–0.881	0.715
Second trimester	52.5 ± 84.7	74.4 ± 137.3	0.228–0.245	0.222
Third trimester	43.3 ± 43.1	168.6 ± 311.5	0.119–0.132	0.120
Fibrinogen overall[†] (mg/dL)	498.3 ± 102.2	481.2 ± 84.5	−23.393–21.150	0.919
First trimester	361 ± 45.7	421 ± 97.2	−179.703–93.703	0.391
Second trimester	502.4 ± 101.8	483.9 ± 94.2	−27.674–26.607	0.967
Third timester	524 ± 89.5	495.6 ± 66.9	−29.549–49.978	0.588
CRP overall (mg/L)	41.2 ± 47.7	25.2 ± 29.0	0.003–0.005	0.004
First trimester	13.6 ± 18.9	14.7 ± 18.8	0.746–0.763	0.581
Second trimester	40.9 ± 41.9	25.2 ± 33.8	0.072–0.082	0.074
Third trimester	47.6 ± 56.1	27.5 ± 26.9	0.023–0.029	0.028
D-Dimer overall[†] (μg FEU/mL)	0.8 ± 0.7	0.8 ± 0.6	−0.079–0.285	0.260
First trimester	0.15 ± 0.06	0.13 ± 0.09	1.000–1.000	0.686
Second trimester	0.61 ± 0.44	0.51 ± 0.23	0.185–0.201	0.309
Third trimester	1.29 ± 0.89	1.34 ± 0.66	0.833–0.847	0.506

[†]Wicoxon rank test and paired samples *t* test. and CI, confidence interval; CRP, C-reactive protein; SD, standard deviation.

retrospective design and lack of data regarding RT-PCR results for cord blood in newborns and mother's breastmilk samples are limitations of this study.

In conclusion, we believe that our results offer a positive contribution to currently available data for the diagnosis and treatment of pregnant COVID-19 patients. Although pregnant women with COVID-19 are no more likely than their nonpregnant counterparts to develop severe pneumonia or to die, early hospitalization and treatment are mandatory to relieve symptoms, to shorten the hospitalization period and to lower the rate of progression to severe pneumonia. Chest CT is a good diagnostic tool in patients who require rapid disease confirmation, as RT-PCR is time-consuming; CT scanning also carries a negligible risk of false-negative results. Finally, the oxygen saturation of all COVID-19 patients should be closely monitored because severe hypoxemia may quickly progress. CRP and procalcitonin are also helpful for monitoring these patients.

Disclosure

All of the authors declare that they have no conflict of interest.

References

1. WHO. Novel coronavirus – China. 12 Jan 2020. [Cited 2 Apr 2020]. Available from URL: http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/
2. WHO Director-General's opening remarks at the media briefing on COVID19. Mar 2020.
3. Wang D, Hu B, Hu C *et al*. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020; **323**(11): 1061–1069. https://doi.org/10.1001/jama.2020.1585. [Epub ahead of print].
4. WHO coronavirus disease 2019 (Covid-19) situation report 46. [Cited 10 May 2020]. Available from URL: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200306-sitrep-46-covid-19.pdf?sfvrsn=96b04adf_4
5. Shi H, Han X, Jiang N *et al*. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. *Lancet Infect Dis* 2020; **20**: 425–434.
6. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. *Radiology* 2020; **296**(2): E32–E40. https://doi.org/10.1148/radiol.2020200642. Epub ahead of print.
7. Wong SF, Chow KM, Leung TN *et al*. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. *Am J Obstet Gynecol* 2004; **191**: 292–297.
8. Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus (MERS-CoV) infection during pregnancy: Report of two cases and review of the literature. *J Microbiol Immunol Infect* 2019; **52**: 501–503.

9. Chen H, Guo J, Wang C *et al*. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. *Lancet* 2020; **395**: 809–815.

10. Liu W, Wang Q, Zhang Q, et al. Coronavirus Disease 2019 (COVID-19) During Pregnancy: A Case Series. *Preprints* 2020, 2020020373.

11. Yu N, Li W, Kang Q *et al*. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: A retrospective, single-centre, descriptive study. *Lancet Infect Dis* 2020; **20**: 559–564.

12. Wang X, Zhou Z, Zhang J, Zhu F, Tang Y, Shen X. A case of 2019 novel coronavirus in a pregnant woman with preterm delivery. *Clin Infect Dis* 2020; **71**(15): 844–846. https://doi.org/10.1093/cid/ciaa200. Epub ahead of print.

13. Liu D, Li L, Wu X *et al*. Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) pneumonia: A preliminary analysis. *AJR Am J Roentgenol* 2020; **215**(1): 127–132. https://doi.org/10.2214/AJR.20.23072. Epub ahead of print.

14. Li N, Han L, Peng M *et al*. Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: A case-control study. *Clin Infect Dis* 2020. https://doi.org/10.1093/cid/ciaa352. Epub ahead of print.

15. Breslin N, Baptiste C, Gyamfi-Bannerman C *et al*. COVID-19 infection among asymptomatic and symptomatic pregnant women: Two weeks of confirmed presentations to an affiliated pair of New York City hospitals. *Am J Obstet Gynecol MFM* 2020; **2**: 100118. https://doi.org/10.1016/j.ajogmf.2020.100118. Epub ahead of print.

16. Della Gatta AN, Rizzo R, Pilu G, Simonazzi G. COVID19 during pregnancy: a systematic review of reported cases. *Am J Obstet Gynecol* 2020; pii: S0002-9378(20)30438-5. https://doi.org/10.1016/j.ajog.2020.04.013. Epubahead of print.

17. Yang Z, Wang M, Zhu Z, Liu Y. Coronavirus disease 2019 (COVID-19) and pregnancy: A systematic review. *J Matern Fetal Neonatal Med* 2020; **30**: 1–4. https://doi.org/10.1080/14767058.2020.1759541. Epub ahead of print.

18. Güneyli S, Atçeken Z, Doğan H, Altınmakas E, Atasoy KC. Radiological approach to COVID-19 pneumonia with an emphasis on chest CT. *Diagn Interv Radiol* 2020; **30**: 323–332. https://doi.org/10.5152/dir.2020.20260. Epub ahead of print.

19. Li K, Wu J, Wu F *et al*. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. *Invest Radiol* 2020; **55**: 327–331.

20. Liu F, Li L, Xu M *et al*. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. *J Clin Virol* 2020; **127**: 104370. https://doi.org/10.1016/j.jcv.2020.104370. Epub ahead of print.

21. Thachil J, Tang N, Gando S *et al*. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *J Thromb Haemost* 2020; **18**: 1023–1026.